Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 51

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 4
Chunk 51
---
/refractory MM and was approved in Europe in 2016, in Japan in 2017 and in China in 2018. In Japan, NINLARO is also approved as a maintenance treatment for MM. In the fiscal year ended March 31, 2025, revenue from NINLARO was JPY 91.2 billion.

•ADCETRIS(brentuximab vedotin), an anti-cancer agent used to treat Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (sALCL), has received marketing authorization in more than 70 countries worldwide and was approved in China in May 2020. Takeda jointly developedADCETRIS with Seagen Inc., now a wholly owned subsidiary of Pfizer Inc. (“ Pfizer”), and has commercialization rights in countries outside the U. S. and Canada. In the fiscal year ended March 31, 2025, our revenue from ADCETRIS was JPY 129.0 billion.

•ICLUSIG (ponatinib), a tyrosine kinase inhibitor targeting BCR::ABL1 with indications across chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), received full approval in the U. S. in 2016 and subsequent U. S. approvals in expanded indications in 2020 and 2024. We have commercialization rights in the U. S. and Australia. Outside of the U. S. and Australia, ICLUSIG is marketed in over 60 markets by five authorized partners from whom Takeda receives

Table of Contents

var ying levels of supply, royalty and milestone payments. In the fiscal year ended March 31, 2025, our revenue from ICLUSIG was JPY 70.7 billion.

In Neuroscience, our principal products are:

•VYVANSE/ELVANSE(lisdexamfetamine dimesylate), a stimulant medication indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients six years and older and for the treatment of moderate to severe binge eating disorder in adults. Sales declined in the U. S. since 2023, following the entry of generic competition. In the fiscal year ended March 31, 2025, our revenue fromVYVANSE/ELVANSE was JPY 350.6 billion.

•TRINTELLIX(vortiox